TY  - GEN
AU  - Verstovsek,S
AU  - Talpaz,M
AU  - Ritchie,E
AU  - Wadleigh,M
AU  - Odenike,O
AU  - Jamieson,C
AU  - Stein,B
AU  - Uno,T
AU  - Mesa,R A
TI  - A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
SN  - 1476-5551
PY  - 2017///0901
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Alleles
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - Biomarkers
KW  - Bone Marrow
KW  - pathology
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Janus Kinase 2
KW  - antagonists & inhibitors
KW  - Male
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Neoplasm Grading
KW  - Phenotype
KW  - Primary Myelofibrosis
KW  - diagnosis
KW  - Protein Kinase Inhibitors
KW  - Retreatment
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/leu.2016.215
ER  -